Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. Show more

Location: Ole Maaloes Vej 3, Copenhagen, 2200, Denmark | Website: https://galecto.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

44.26M

52 Wk Range

$2.01 - $33.60

Previous Close

$27.79

Open

$26.54

Volume

143,597

Day Range

$26.54 - $29.97

Enterprise Value

38.06M

Cash

7.606M

Avg Qtr Burn

-3.057M

Insider Ownership

3.57%

Institutional Own.

13.38%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GB1211 (oral galectin-3 inhibitor) + pembrolizumab (Keytruda®) Details Cancer, Head and neck squamous cell carcinoma, Melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1211 (oral galectin-3 inhibitor) Details Cirrhosis, Non-alcoholic steatohepatitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details Non-small cell lung carcinoma, Cancer, Fibrosis	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB3226 (formerly BRM-1420) Details Acute myeloid leukemia, Blood cancer, Cancer	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB2064 (oral LOXL2 inhibitor) Details Fibrosis, Myelofibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB0139 (inhaled galectin-3 inhibitor) Details Fibrosis, Pulmonary fibrosis, Lung disease, Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.